CiMaas

CiMaas is a clinical-stage biotechnology company based in the Netherlands that specializes in the development of innovative cellular immuotherapies for cancer. The company focuses on two primary technology platforms: a unique method for the large-scale expansion and activation of Natural Killer (NK) cells and a high-potency Dendritic Cell (DC) vaccine. CiMaas aims to provide cost-effective and highly active cell-based treatments to improve the survival and quality of life for patients with hematological malignancies and solid tumors. Their lead program involves ex vivo expanded NK cells for the treatment of multiple myeloma.